Top Page
Shanghai Junshi Biosciences Co., Ltd. Class H
(1877)
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Junshi Biosciences Co., Ltd. Class H Business Overview & Revenue Model
Shanghai Junshi Biosciences Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.54B | 1.95B | 1.50B | 1.45B | 4.02B | 1.59B |
| Gross Profit | 2.08B | 1.54B | 835.26M | 927.21M | 2.77B | 1.22B |
| EBITDA | -745.31M | -935.50M | -2.16B | -2.52B | -476.32M | -1.58B |
| Net Income | -966.82M | -1.28B | -2.28B | -2.39B | -718.56M | -1.67B |
Balance Sheet | ||||||
| Total Assets | 12.77B | 10.80B | 11.36B | 12.58B | 11.05B | 8.01B |
| Cash, Cash Equivalents and Short-Term Investments | 3.57B | 2.93B | 3.78B | 6.00B | 3.50B | 3.39B |
| Total Debt | 3.92B | 2.93B | 1.79B | 1.32B | 628.20M | 850.78M |
| Total Liabilities | 5.89B | 4.85B | 4.02B | 2.78B | 2.72B | 2.17B |
| Stockholders Equity | 6.79B | 5.86B | 7.17B | 9.50B | 7.96B | 5.84B |
Cash Flow | ||||||
| Free Cash Flow | -1.28B | -2.12B | -2.85B | -2.17B | -1.53B | -2.09B |
| Operating Cash Flow | -681.74M | -1.43B | -2.01B | -1.78B | -641.90M | -1.50B |
| Investing Cash Flow | -745.27M | -892.78M | -892.42M | -467.62M | -1.88B | -697.98M |
| Financing Cash Flow | 1.70B | 1.02B | 681.04M | 4.64B | 2.67B | 4.41B |
Shanghai Junshi Biosciences Co., Ltd. Class H Technical Analysis
Shanghai Junshi Biosciences Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$36.41B | 40.91 | 27.37% | ― | 2.57% | 18.79% | |
53 Neutral | HK$10.65B | 41.67 | 13.34% | ― | 206.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | HK$20.35B | -14.02 | -161.12% | ― | -56.94% | -190.36% | |
42 Neutral | HK$16.21B | -9.55 | -30.41% | ― | 23.87% | 30.08% | |
40 Neutral | HK$57.70B | -50.14 | -39.64% | ― | 46.14% | 39.56% | |
38 Underperform | HK$40.05B | -24.53 | -15.06% | ― | 38.56% | 48.26% |
Shanghai Junshi Biosciences Co., Ltd. Class H Corporate Events
Shanghai Junshi Biosciences has revised the expected timetable for using the remaining proceeds from its 2022 issuance of A shares, primarily earmarked for innovative drug R&D projects and the construction of its Shanghai biotech headquarters and R&D base. As of 30 June 2025, RMB 1.181 billion of the RMB 3.745 billion raised had been utilized, and the company now expects to fully deploy the outstanding funds for innovative drug R&D by 31 December 2028 and for the headquarters and R&D base project by 30 June 2026, reflecting adjustments driven by actual project progress, changes in certain sub-projects, and clinical development timelines while maintaining the original investment scope, use and implementing entities.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$21.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences has obtained regulatory acceptance from the National Association of Financial Market Institutional Investors for the registration of up to RMB20 billion in medium-term technology innovation bonds, which will be underwritten by Bank of Shanghai and remain valid for issuance over a two-year period. The company plans to issue these bonds in tranches based on its capital needs and market conditions, potentially strengthening its funding capacity for innovation-driven projects, while cautioning investors that the bond issuance may or may not proceed and that results will be disclosed through officially recognized channels.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$21.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences has announced that substantial shareholder Shanghai Tanying Investment Partnership (LP), which currently holds 59,459,326 A shares representing about 5.79% of the company’s total share capital, plans to reduce its stake due to fund maturity and liquidity needs. Under approved share reduction policies for venture capital fund shareholders, Shanghai Tanying intends to sell up to 20,533,797 shares, or no more than 2% of Junshi’s total share capital, via block trading, a move that may modestly increase the stock’s free float while signaling that the shareholder remains optimistic about the company’s long‑term prospects despite trimming its position.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. FDA has approved its investigational new drug application for JS212, a bispecific antibody-drug conjugate targeting EGFR and HER3 for advanced solid tumors. This approval marks a significant step in the company’s research and development efforts, potentially enhancing its position in the oncology market by addressing drug resistance and expanding treatment options for a wider range of tumors.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that its chairman, Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB100 million over the next 12 months, with a significant portion allocated to A shares. As of now, Mr. Xiong has already acquired 100,000 A shares, representing 0.01% of the company’s total share capital, through the Shanghai Stock Exchange. This move is aimed at strengthening the company’s market position and reflects confidence in its future growth prospects, although it is subject to market conditions and other unforeseen risks.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that two new indications for its products, Toripalimab Injection (TUOYI) and Ongericimab Injection (JUNSHIDA), have been added to China’s National Reimbursement Drug List (NRDL) effective January 2026. This inclusion marks a significant milestone for the company, as all 12 indications of TUOYI are now covered, making it the only anti-PD-1 monoclonal antibody in the NRDL for renal cancer, TNBC, and melanoma. JUNSHIDA’s inclusion is notable as it is the only domestic PCSK9-targeted drug for statin-intolerant patients in the NRDL, enhancing the company’s market positioning and potential stakeholder benefits.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced the acceptance of its new drug application for Roconkibart Injection by the National Medical Products Administration. This drug, aimed at treating moderate to severe plaque psoriasis, has shown significant efficacy in clinical trials and represents a potential advancement in the treatment of autoimmune diseases, enhancing the company’s position in the pharmaceutical industry.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced a reduction in shareholding by Shanghai Tanying Investment Partnership, which previously held over 6.96% of the company’s total share capital. This decision follows the maturity of the fund and liquidity arrangements, impacting the company’s shareholder structure and potentially influencing market perceptions of its financial strategy.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced a change in equity holdings, with shareholders holding more than 5% of shares reducing their stake from 5.0051% to 4.7129%. This change does not breach any commitments or trigger a mandatory tender offer obligation, indicating a strategic adjustment in shareholder composition without significant operational impact.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced a new cash management strategy involving the use of temporarily idle proceeds to purchase principal guaranteed investment products with high security and good liquidity. This move aims to improve the efficiency of fund utilization without affecting the company’s ongoing investment plans, and it has been approved by the Board of Directors, with a validity of 12 months.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that its phase III clinical study of JS001sc, a subcutaneous injection formulation for the first-line treatment of non-squamous non-small cell lung cancer (NSCLC), has met its primary endpoints. This development marks a significant step in providing a more convenient administration method for immunotherapy, potentially enhancing patient experience and positioning the company as a leader in domestic anti-PD-1 monoclonal antibody treatments. The company plans to submit a new drug application to regulatory authorities, which could impact its market presence and offer new options for NSCLC patients.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has completed the registration of its First Grant of A Share Options under the 2025 A Share Option Incentive Scheme, following shareholder approval. The scheme involves 24,700,000 A Share Options granted to 226 participants, including employees and a substantial shareholder, with specific vesting and exercise conditions outlined for the options. This initiative is expected to enhance stakeholder engagement and align employee interests with company growth objectives.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that its chairman, Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB100 million, with a minimum of RMB50 million allocated to A shares. As of the announcement date, Mr. Xiong Jun has already acquired 100,000 A shares, representing 0.01% of the company’s total share capital, through the Shanghai Stock Exchange. This move reflects confidence in the company’s future prospects, although the plan’s completion is subject to market conditions and other unpredictable risk factors.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has released its unaudited financial results for the third quarter of 2025, reporting a significant increase in operating income. The company’s revenue rose by 31.40% during the reporting period and by 42.06% from the beginning of the year, highlighting its strong market performance and potential positive impact on its stakeholders.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that its wholly-owned subsidiary, Suzhou Union Biopharm Co., Ltd., has successfully passed an unannounced FDA on-site inspection for Current Good Manufacturing Practice (CGMP) compliance. This achievement marks the second successful FDA inspection for Suzhou Union, reinforcing the company’s high production standards and supporting its expansion strategy in the U.S. market. The successful inspection is expected to positively impact the company’s operations and strengthen its position in the global pharmaceutical industry.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced the convening of its 2025 third quarterly results briefing, scheduled for October 29, 2025. The briefing aims to provide investors with a comprehensive understanding of the company’s operating results and financial status for the third quarter of 2025, facilitating communication between the company and its stakeholders.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. FDA has approved its investigational new drug application for a phase II/III clinical study of JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, for the neoadjuvant treatment of non-small cell lung cancer (NSCLC) patients. This approval marks a significant step for the company as it positions JS207 as a potential new treatment option for NSCLC, addressing unmet clinical needs and potentially improving patient outcomes in a highly prevalent and deadly cancer type.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. has announced that its board of directors will meet on October 28, 2025, to review and approve the company’s unaudited financial results for the nine months ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and performance, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$29.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
Shanghai Junshi Biosciences Co., Ltd. announced that its chairman, Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB100 million, with a minimum of RMB50 million allocated to A shares. As of October 2025, the shareholding increase plan has reached its midpoint, but due to various factors such as reporting windows and funding arrangements, the increase has not yet been completed. Mr. Xiong Jun intends to continue with the shareholding increase plan as opportunities arise, which may impact the company’s market position and shareholder confidence.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.